JANUARY 26 - 28, 2023

VIEW THE 2023 RECORDED SESSIONS

We would like to sincerely thank you for your interest in the sixth Symposium on Hepatic Oncology at Whistler (SHOW), to be held as a hybrid event on January 26 to 28, 2023.

We have resurrected this meeting by popular demand. In the past three years GI malignancies has represented a rapidly evolving field with many ‘hot topics’. We will to continue to focus on hepatocellular carcinoma (HCC), pancreatico-biliary and metastatic colorectal carcinoma (mCRC). The purpose of SHOW is to present practical cross disciplinary perspectives on the treatment of liver cancers given recent literature and developments. As such, we have established four chairs, Dr. Andrew Kennedy of Radiation Oncology, Dr. Peter Kim of Hepatobiliary Surgery, Dr. Wendy Lam of Medical Oncology and Dr. David Liu of Interventional Radiology for this conference to foster a collaborative approach to patient care through didactic talks, case presentations and panel discussion.

At its core, we have selected faculty both locally and internationally that have worked extensively in the context of multidisciplinary management of complex hepatobiliary oncology. We will also provide a Canadian perspective on the topics.

Thank you and we look forward to welcoming you to SHOW 2023!

Sincerely,

Chairs, Symposium on Hepatic Oncology at Whistler (SHOW) 2023

David Liu MD FRCPC FSIR
Associate Professor, Department of Radiology, Faculty of Medicine, University of British Columbia
Associate Professor, School of Biomedical Engineering, Faculty of Applied Sciences, University of British Columbia
Voluntary Professor, Department of Interventional Radiology, Miller School of Medicine, University of Miami
Vancouver, BC

Wendy Lam, B Sc (Pharm), MD, FRCP(C)
Hematologist/Oncologist
Director, BC Community Oncology Trialists
Burnaby Hospital Regional Cancer Centre
Burnaby, BC

Andrew Kennedy, MD, FACRO
Physician in Chief, Radiation Oncology, Sarah Cannon
Director, Radiation Oncology Research, Sarah Cannon Research Institute
Sarah Cannon Cancer Center
Nashville, TN

Peter TW Kim MD, MSc, FRCSC, FACS
Head, Liver Transplant Program
Head, Hepatopancreatobiliary Surgery
Vancouver General Hospital
Clinical Associate Professor
University of British Columbia
Vancouver, BC

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

This activity was approved by the Canadian Association of Medical Oncologists for a maximum of 16 hours.

Learning Objectives:

Establish principles of liver-directed locoregional therapy in the setting of pancreatic neuroendocrine disease, hepatocellular carcinoma and metastatic colorectal carcinoma.
Review evidence base for systemic, surgical, ablative and embolic strategies in liver-directed therapies in HCC mCRC and pNET.
Provide context for locoregional therapy as it relates to the timing of systemic therapies.
Engage in case-based panels that exemplify the role of multidisciplinary board review.
Demonstrate the synergies and optimization of therapeutic options in the treatment of both primary and metastatic liver cancer.
Create a forum for open discussion and cross disciplinary knowledge translation.
Assess recent advances in systemic treatment of hepatocellular carcinoma, pancreatic neuroendocrine disease, and colorectal cancer.
Facilitate direct discussion and interaction with world recognized disease experts.

Target Audience

- Physicians, nurses, allied health professionals, and trainees with a scope of practice that involves management of both primary and hepatic neoplasia. Topics and themes will focus on practical and community-based practice.